Denali Therapeutics Earnings
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Thu, Nov 5, 2026
Fiscal period
Sep/2026
EPS estimate
$-0.67
Denali Therapeutics earnings summary
Denali Therapeutics is scheduled to report Sep/2026 earnings on Nov 5, 2026, with analysts expecting EPS of $-0.67. In its most recent report on Aug 6, 2026 (Q2 2026), DNLI posted EPS of $-0.68. Revenue for the quarter was $3.6 million.
Across the last 16 reports, DNLI shares moved an average of 8.7% (in either direction) in the first trading session after results, rising 9 times and falling 7 times.
Summary generated from market data by MetaCap's automated system. Methodology
DNLI earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 6, 2026 | — | $-0.68 | — | -1.7% |
| May 7, 2026 | — | $-0.69 | — | -5.1% |
| Feb 26, 2026 | — | $-0.73 | — | -7.0% |
| Nov 6, 2025 | — | $-0.74 | — | +16.1% |
| Aug 11, 2025 | — | $-0.72 | — | +5.4% |
| May 6, 2025 | — | $-0.78 | — | -4.1% |
| Feb 27, 2025 | — | $-0.67 | — | +0.8% |
| Nov 6, 2024 | — | $-0.63 | — | -20.1% |
| Aug 1, 2024 | — | $-0.59 | — | +2.4% |
| May 7, 2024 | — | $-0.68 | — | +12.0% |
| Feb 28, 2024 | — | $-0.84 | — | +0.3% |
| Nov 7, 2023 | — | $-0.72 | — | +15.7% |
| Aug 8, 2023 | — | $1.30 | — | -6.3% |
| May 8, 2023 | — | $-0.80 | — | +12.9% |
| Feb 27, 2023 | — | $-0.75 | — | -16.5% |
| Nov 3, 2022 | — | $-0.84 | — | +12.3% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.